United Therapeutics (NASDAQ:UTHR) Sets New 52-Week High – Here’s What Happened

United Therapeutics Corporation (NASDAQ:UTHR) reached a new 52-week high during trading on Thursday . The company traded as high as $513.93 and last traded at $510.94, with a volume of 613498 shares traded. The stock had previously closed at $500.00.

More United Therapeutics News

Here are the key news stories impacting United Therapeutics this week:

• Positive Sentiment: Director Tommy G. Thompson sold 910 shares but still holds 8,480 shares (~$4.25M), signaling continued insider alignment with shareholders. SEC Filing — Thompson Sale
• Neutral Sentiment: All transactions were disclosed via SEC filings and covered by financial sites, providing transparency; investors should check the filings for whether sales were part of pre-set programs (e.g., 10b5-1) that reduce interpretive weight. SEC Filings
• Negative Sentiment: CEO Martine A. Rothblatt sold a total of 6,000 shares across Dec. 17 and Dec. 19 at ~ $501–$507, leaving her with only 130 shares — a ~94%+ reduction in reported ownership; that sharp drop can be read as a meaningful negative signal to some investors. SEC Filing — Rothblatt Sales
• Negative Sentiment: Additional senior insider sales: CFO and COO transactions reported (CFO ~$1.74M; COO ~$11.17M), increasing the volume and scope of executive selling within days — a likely near-term headwind for sentiment absent an explanatory disclosure. ABN: CEO Sale Coverage ABN: CFO Sale Coverage ABN: COO Sale Coverage

Analysts Set New Price Targets

Several research firms recently issued reports on UTHR. UBS Group lifted their price target on shares of United Therapeutics from $580.00 to $600.00 and gave the stock a “buy” rating in a research note on Thursday, November 6th. Royal Bank Of Canada raised their target price on United Therapeutics from $569.00 to $587.00 and gave the company an “outperform” rating in a research note on Thursday, October 30th. Morgan Stanley set a $447.00 price target on United Therapeutics in a research note on Wednesday, October 29th. Wells Fargo & Company raised their price objective on United Therapeutics from $414.00 to $423.00 and gave the company an “equal weight” rating in a research note on Thursday, October 30th. Finally, Weiss Ratings reaffirmed a “buy (b-)” rating on shares of United Therapeutics in a research report on Monday, December 8th. Eight investment analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company’s stock. According to MarketBeat.com, United Therapeutics has a consensus rating of “Moderate Buy” and an average target price of $505.00.

United Therapeutics Stock Up 2.0%

The firm has a market capitalization of $22.27 billion, a price-to-earnings ratio of 19.60, a P/E/G ratio of 5.03 and a beta of 0.86. The stock has a 50 day moving average of $463.63 and a 200 day moving average of $380.56.

United Therapeutics (NASDAQ:UTHR) last announced its quarterly earnings data on Wednesday, October 29th. The biotechnology company reported $7.16 earnings per share (EPS) for the quarter, beating the consensus estimate of $6.89 by $0.27. United Therapeutics had a return on equity of 18.83% and a net margin of 40.65%.The firm had revenue of $799.50 million for the quarter, compared to analysts’ expectations of $812.87 million. During the same quarter in the prior year, the firm posted $6.39 earnings per share. United Therapeutics’s revenue for the quarter was up 6.8% compared to the same quarter last year. Analysts predict that United Therapeutics Corporation will post 24.48 earnings per share for the current year.

Insider Transactions at United Therapeutics

In other United Therapeutics news, COO Michael Benkowitz sold 22,500 shares of United Therapeutics stock in a transaction on Monday, October 6th. The shares were sold at an average price of $450.24, for a total value of $10,130,400.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Insiders sold 625,164 shares of company stock worth $284,916,107 in the last quarter. Company insiders own 10.30% of the company’s stock.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of UTHR. CWM LLC raised its position in United Therapeutics by 204.3% in the second quarter. CWM LLC now owns 5,194 shares of the biotechnology company’s stock worth $1,492,000 after acquiring an additional 3,487 shares in the last quarter. AXQ Capital LP grew its stake in shares of United Therapeutics by 495.4% in the 2nd quarter. AXQ Capital LP now owns 3,888 shares of the biotechnology company’s stock worth $1,117,000 after purchasing an additional 3,235 shares during the last quarter. Osaic Holdings Inc. raised its holdings in shares of United Therapeutics by 271.0% in the 2nd quarter. Osaic Holdings Inc. now owns 46,082 shares of the biotechnology company’s stock worth $14,027,000 after purchasing an additional 33,662 shares in the last quarter. Wealth Enhancement Advisory Services LLC raised its holdings in shares of United Therapeutics by 77.4% in the 2nd quarter. Wealth Enhancement Advisory Services LLC now owns 6,084 shares of the biotechnology company’s stock worth $1,792,000 after purchasing an additional 2,655 shares in the last quarter. Finally, State of Alaska Department of Revenue lifted its stake in United Therapeutics by 17.0% during the second quarter. State of Alaska Department of Revenue now owns 19,532 shares of the biotechnology company’s stock valued at $5,612,000 after purchasing an additional 2,840 shares during the last quarter. 94.08% of the stock is currently owned by institutional investors.

United Therapeutics Company Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.